Our lead candidate, INZ-701, is in clinical development for the potential treatment of ENPP1 Deficiency and ABCC6 Deficiency, which are driven by low levels of inorganic pyrophosphate (PPi) andadenosine. Currently, there are no therapeutic options for patients suffering from ENPP1 Deficiency and ABCC6 Deficiency –  two rare disorders. We are pioneering the development of effective therapies for these patients and their families.